PIK3CA and acute lymphoblastic leukemia: Taken these findings together we believe that the efficacy observed in the treated ALL patients warrants a further clinical exploration of dual PI3K/mTOR inhibition potentially as combination therapy with other small molecules or chemotherapeutics.